Seattle Genetics, a clinical biotech company, has finally made it to a mainstream level thanks to its rigorous research, its scientific development, and its drug innovations. These three core principles have come from Clay Siegall, the president and co-founder of Seattle Genetics. Siegall is definitely a man of many talents. Many of his peers refer to him as being a doctor, a scientist, an author and a philanthropist. Siegall has an extensive educational base that dates back to over 30 years. He has a first-hand accounting of cancer because his father suffered with the disease for many years.
While in college, Siegall’s father become ill. During this point in time, cancer treatments were extremely rough on the human body. In some cases, amputations made its way into the range of treatments. These treatments were extremely harsh and Siegall knew that there had to be a better way. This is why he has dedicated his life to fighting this deadly disease. Siegall actually co-founded one of the world’s top biotech companies that specialize in treating cancer. Seattle Genetics may not look awe-inspiring from the outside, but it certainly has a ton of technological advancements on the inside. The company is located in Bothell, Washington, and it has nearly 1,000 employees. Targeted-cancer therapies are what Seattle Genetics is known for, and it produces some of the very best. The company’s premier drug, ADCETRIS, has gone on to serve and heal millions of people on a global scale. As of today, ADCETRIS is being used in over 60 countries worldwide.
Siegall has come a long way since the birth of Seattle Genetics. The company isn’t struggling anymore, and it is worth billions of dollars. In just a few short years, Seattle Genetics’ stock has roughly tripled. This is absolutely correct and much of this grand success has come from Clay Siegall.